Drugs / 18F-fluoroglutamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05452889 | Jul 2022 → Jan 2027 expected | pulmonary arterial hypertension | Stephen Y. Chan | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-fluoroglutamine | “18F-fluoroglutamine (18F-FGln)” NCT05452889 ↗ |
| Known as | 18F-FGln | “18F-fluoroglutamine (18F-FGln)” NCT05452889 ↗ |
| Modality | Diagnostic / imaging agent | “non-invasive imaging biomarker” NCT05452889 ↗ |
| Route | Intravenous | “10.0 mCi of 18F-FGln will be injected intravenously as a slow bolus (20 sec)” NCT05452889 ↗ |